Preventing memory decline in Parkinson's with GBA gene changes
Part of Brain & nervous system clinical trials.
This study tests whether an experimental drug called prasinezumab can help prevent memory and thinking problems in people with Parkinson's disease who carry a specific GBA gene change. It aims to slow down cognitive decline and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Parkinson's disease diagnosed by a movement disorder specialist.
- You have a specific change in the GBA gene (called a severe mutation) that is linked to Parkinson's.
- Your thinking and memory are still fairly good (score of 21 or higher on a standard test).
- You are between 35 and 80 years old.
- You are not currently taking certain Parkinson's medications unless they have been stable for at least 90 days.
- You have not had deep brain stimulation (DBS) surgery or plan to have it within the next 2 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication called prasinezumab, given through a vein (IV), to see if it can slow the progression of early-stage Parkinson's disease. It is for people who are on only one Parkinson's medication and have not yet developed motor complications.
This trial tests a new gene therapy for Parkinson's disease in people who have a specific genetic change (GBA1 mutation) that may be causing their symptoms. The treatment aims to fix the root cause by delivering a corrected gene to the brain, which might help improve motor symptoms and reduce 'off' time.
This study looks at how a protein called alpha-synuclein spreads in Parkinson's disease by checking blood and brain scans. It aims to understand why some people develop Parkinson's and to find clues that could lead to better treatments.
This study looks at early (before full disease) Parkinson-like symptoms in people who carry a specific genetic change called GBA1. It may help researchers understand who could develop Parkinson’s and how early signs can be tracked.
This trial tests an experimental gene therapy injected directly into the brain, designed for people with Parkinson's disease who carry a specific genetic change called GBA1. The goal is to see if the treatment is safe, tolerable, and helps improve motor symptoms.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
Hear when a new Parkinson’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.